Certara (NASDAQ:CERT) Price Target Raised to $7.50

Certara (NASDAQ:CERT) had its target price lifted by Barclays from $6.50 to $7.50 in a research note released on Wednesday morning, MarketBeat reports. They currently have an equal weight rating on the stock.

Several other brokerages also recently weighed in on CERT. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. Craig Hallum cut their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th. KeyCorp cut their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, April 13th. Stephens reduced their price objective on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Robert W. Baird decreased their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.28.

Certara Stock Up 0.9%

CERT stock opened at $8.20 on Wednesday. Certara has a twelve month low of $4.45 and a twelve month high of $13.88. The company has a quick ratio of 1.88, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.25 billion, a PE ratio of -18.22 and a beta of 1.44. The business has a 50 day moving average of $6.56 and a 200 day moving average of $6.55.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. During the same quarter in the previous year, the firm posted $0.07 EPS. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, research analysts forecast that Certara will post 0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after acquiring an additional 2,870 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares in the last quarter. State of Wyoming purchased a new stake in shares of Certara in the 2nd quarter worth $72,000. Finally, Pacer Advisors Inc. raised its holdings in Certara by 28.1% in the 1st quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.